Moloney Securities Asset Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $120K | Buy |
501,560
+1,440
| +0.3% | +$345 | 0.01% | 459 |
|
|
2025
Q1 | $114K | Buy |
500,120
+11,600
| +2% | +$2.65K | 0.02% | 451 |
|
|
2024
Q4 | $134K | Buy |
488,520
+26,305
| +6% | +$7.23K | 0.02% | 433 |
|
|
2024
Q3 | $148K | Buy |
462,215
+37,905
| +9% | +$12.1K | 0.02% | 449 |
|
|
2024
Q2 | $181K | Buy |
424,310
+44,850
| +12% | +$19.1K | 0.03% | 431 |
|
|
2024
Q1 | $197K | Buy |
379,460
+21,300
| +6% | +$11.1K | 0.03% | 414 |
|
|
2023
Q4 | $251K | Buy |
358,160
+5,500
| +2% | +$3.86K | 0.04% | 359 |
|
|
2023
Q3 | $321K | Buy |
352,660
+23,000
| +7% | +$20.9K | 0.06% | 304 |
|
|
2023
Q2 | $187K | Buy |
329,660
+45,500
| +16% | +$25.8K | 0.03% | 379 |
|
|
2023
Q1 | $178K | Sell |
284,160
-1,300
| -0.5% | -$813 | 0.03% | 383 |
|
|
2022
Q4 | $224K | Buy |
285,460
+300
| +0.1% | +$235 | 0.05% | 344 |
|
|
2022
Q3 | $204K | Buy |
285,160
+700
| +0.2% | +$501 | 0.05% | 336 |
|
|
2022
Q2 | $179K | Buy |
284,460
+5,995
| +2% | +$3.77K | 0.04% | 340 |
|
|
2022
Q1 | $194K | Buy |
278,465
+46,400
| +20% | +$32.3K | 0.04% | 381 |
|
|
2021
Q4 | $162K | Buy |
232,065
+63,800
| +38% | +$44.5K | 0.03% | 416 |
|
|
2021
Q3 | $215K | Buy |
168,265
+8,600
| +5% | +$11K | 0.04% | 383 |
|
|
2021
Q2 | $235K | Buy |
159,665
+20,720
| +15% | +$30.5K | 0.04% | 367 |
|
|
2021
Q1 | $207K | Buy |
138,945
+34,895
| +34% | +$52K | 0.04% | 372 |
|
|
2020
Q4 | $159K | Buy |
104,050
+54,650
| +111% | +$83.5K | 0.04% | 359 |
|
|
2020
Q3 | $38K | Buy |
49,400
+17,400
| +54% | +$13.4K | 0.01% | 323 |
|
|
2020
Q2 | $11K | Buy |
32,000
+1,000
| +3% | +$344 | ﹤0.01% | 304 |
|
|
2020
Q1 | $5K | Buy |
+31,000
| New | +$5K | ﹤0.01% | 281 |
|